Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1647 1658 1683
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18048547 | SITE-SELECTIVE LYSINE ACETYLATION OF HUMAN IMMUNOGLOBULIN G AND IgG-RELATED PRODUCTS FOR IMMUNOTHERAPY | Final Rejection | The Chinese University of Hong Kong |
| 18249057 | USE OF REELIN FOR TREATING CARDIAC DISEASES | Non-Final OA | Northwestern University |
| 16951638 | METHOD OF USING CHECKPOINT KINASE INHIBITOR THERAPY TO MODULATE ANTI-TUMORAL RESPONSE AGAINST CANCER AND SENSITIZE GLIOMAS TO IMMUNOTHERAPY | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 17758830 | IL2 Orthologs and Methods of Use | Non-Final OA | Synthekine, Inc. |
| 17348706 | Methods for the Diagnosis and Treatment of Biofilm-Related Infections | Final Rejection | Laboratory Corporation of America Holdings |
| 17434692 | INDUCTION OF HIGHLY EFFICACIOUS ANTI-TUMOR AND IMMUNE MODULATING ACTIVITY: CELL-FREE OFF THE SHELF THERAPEUTIC MODALITY | Non-Final OA | Wayne State University |
| 17318017 | METHODS AND COMBINATIONS FOR THE TREATMENT OF CANCER USING IMMUNE CHECKPOINT INHIBITOR ANTIBODIES | Final Rejection | ASTRAZENECA AB |
| 17255383 | COMPOSITIONS AND METHODS FOR ANTIBODY DELIVERY | Final Rejection | Krystal Biotech, Inc. |
| 18021845 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18160535 | Compositions and Methods for Tendon Regeneration | Non-Final OA | University of Rochester |
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | Non-Final OA | Baylor College of Medicine |
| 18269633 | COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION | Non-Final OA | VOR BIOPHARMA INC. |
| 17242647 | Method For The Degradation Of Endogenous Protein | Final Rejection | University of South Carolina |
| 18332571 | ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF | Non-Final OA | Research Development Foundation |
| 18238650 | ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF | Final Rejection | Trustees of Tufts College |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18551502 | Pharmaceutical Combinations for Treating Cancer | Non-Final OA | T3 PHARMACEUTICALS AG |
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | Non-Final OA | MEDIGENE IMMUNOTHERAPIES GMBH |
| 18546798 | STABILIZED PRE-FUSION RSV FB ANTIGENS | Non-Final OA | Janssen Vaccines & Prevention B.V. |
| 18276639 | ANTI-CD112R ANTIBODY AND USE THEREOF | Non-Final OA | SUZHOU JUNMENG BIOSCIENCES CO., LTD. |
| 16894532 | TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS | Non-Final OA | HUYABIO International, LLC |
| 18261059 | CD5-TARGETING FULLY HUMANIZED ANTIBODY | Non-Final OA | Nanjing IASO Biotechnology Co., Ltd. |
| 18266600 | ANTI-TNFR2 ANTIBODY AND APPLICATION THEREOF | Non-Final OA | ADLAI NORTYE BIOPHARMA CO., LTD. |
| 18255342 | TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS | Non-Final OA | APTEVO RESEARCH AND DEVELOPMENT LLC |
| 18324935 | NOVEL ANTI-LAG3 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | SHANGHAI BENEMAE PHARMACEUTICAL CORPORATION |
| 18020837 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | Non-Final OA | A2 Biotherapeutics, Inc. |
| 18198404 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | Non-Final OA | President & Fellows of Harvard College |
| 18119487 | MODIFIED CELLS OF LEUKEMIC ORIGIN AND A PD-L1 ANTIBODY FOR ENHANCING THE EFFICACY OF CANCER CELL THERAPY | Non-Final OA | Mendus B.V. |
| 18249154 | COMBINATION OF ADOPTIVE CELL THERAPY AND CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA | Non-Final OA | LOMA LINDA FACULTY MEDICAL GROUP |
| 17757825 | METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE | Final Rejection | Eisai R&D Management Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy